Comparison of drug-related problem risk assessment tools for older adults : a systematic review by Puumalainen, Emmi et al.
REVIEW
Comparison of drug-related problem risk assessment tools for older
adults: a systematic review
Emmi Puumalainen1 & Marja Airaksinen1 & Sanni E. Jalava1 & Timothy F. Chen2 & Maarit Dimitrow1
Received: 28 April 2019 /Accepted: 5 November 2019
# The Author(s) 2019
Abstract
Purpose This study aims to systematically review studies describing screening tools that assess the risk for drug-related problems
(DRPs) in older adults (≥ 60 years). The focus of the review is to compare DRP risks listed in different tools and describe their
development methods and validation.
Methods The systematic search was conducted using evidence-based medicine, Medline Ovid, Scopus, and Web of Science
databases from January 1, 1985, to April 7, 2016. Publications describing general DRP risk assessment tools for older adults
written in English were included. Disease, therapy, and drug-specific tools were excluded. Outcome measures included an
assessment tool’s content, development methods, and validation assessment.
Results The search produced 15 publications describing 11 DRP risk assessment tools. Three major categories of risks for DRPs
included (1) patient or caregiver related risks; (2) pharmacotherapy-related risks; and (3) medication use process-related risks. Of
all the risks included in the tools only 8 criteria appeared in at least 4 of the tools, problems remembering to take the medication
being the most common (n=7). Validation assessments varied and content validation was the most commonly conducted (n = 9).
Reliability assessment was conducted for 6 tools, most commonly by calculating internal consistency (n = 3) and inter-rater
reliability (n = 2).
Conclusions The considerable variety between the contents of the tools indicates that there is no consensus on the risk factors for
DRPs that should be screened in older adults taking multiple medicines. Further research is needed to improve the accuracy and
timeliness of the DRP risk assessment tools.
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Introduction
Drug-related risk management has become an important area of
research in patient safety. It is estimated that approximately half of
the drug-related incidents contributing to severe harm could be
prevented by managing risks through interventions at different
points of the medication use process [1]. The World Health
Organization’s (WHO)program,MedicationWithoutHarm,aims
to globally reduce severe avoidable drug-related harm by 50% in
5 years [2]. Drug-related riskmanagement aims at reducingmed-
ication errors that might potentially or actually cause drug-related
problems (DRPs) or risk of DRPs [3]. A DRP is an event or
circumstance involving drug therapy that actually or potentially
interfereswith desired health outcomes (PCNE) [4]. Another def-
inition for aDRP emphasizes that aDRP can either cause harmor
result in medication treatment not reaching its goal [5].
Identification of actual or potential risk factors for DRPs
should be considered an essential part of safe medication use
particularly in older adults. Although there is considerable
research on explicit criteria assessing inappropriate prescrib-
ing, these criteria mainly target a small part of the whole prob-
lem [6]. DRP’s can occur in any phase of the medication use
process. Through DRP risk identification in patient selection
for different interventions, DRPs can be identified and re-
solved with a more targeted approach. DRP risk assessment
tools have been developed taking into consideration special
features of geriatric patients. However, the content of these
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tools have not been systematically reviewed. The objective of
this study was to systematically review the content of screen-
ing tools intended for assessing risks for DRPs in older adults
(≥ 60 years). The focus of the review was to compare DRP
risk factors in different tools and describe the methods applied
in their development and validation.
Methods
Search strategy and literature search
This systematic review conformed to the PRISMA checklist
[7, 8]. The evidence-based medicine (EBM), Scopus, and
Web of Science (WOS) databases were searched from
January 1, 1985, till April 6, 2016 and Medline Ovid database
from January 1, 1985, till April 7, 2016 for eligible publica-
tions. The search terms used in the systematic search were
((elderly OR aged OR ageing) AND ("medication-related
problem*" OR "drug-related problem*" OR "drug therapy
problem*" OR “medicine-related problem*” OR “medication
management problem*” OR “therapy-related problem* OR
“DRP*”) AND (risk OR risk assessment) AND (screen OR
"screening tool" OR form OR assessment* OR evaluation*
OR indicator* OR criteria OR survey* OR questionnaire* OR
factor* OR “risk factor*)). CINAHL database was included in
the pilot search but was excluded from further searches be-
cause of a very low number of potentially relevant publica-
tions. Thus, the results for the CINAHL database are reported
according to the pilot search on October 29, 2013.
The publications found in the searches (n = 4279) were first
evaluated according to the predetermined inclusion and exclu-
sion criteria (Table 1) by one of the authors (EP) by reading
the title (Fig. 1). Then two authors (EP and SJ) assessed the
publications independently by reading the abstract (n = 196)
and finally by reading the whole text (n = 54). Duplicates (n =
34) were excluded before reading the full-texts. Any disagree-
ments were resolved through discussion. Reasons for exclu-
sion of the full-text publications (n = 44) are reported in Fig. 1.
A manual search of the references and author’s own collection
of publications was conducted (EP), and 5 publications meet-
ing inclusion criteria were discovered, one of which was not
explicitly meant for older adults [9]. This publication was
included in the review due to its importance for development
of other DRP risk assessment tools. Of these five publications,
two were received from the authors of included publications
as additional information [10, 11]. Manually researched pub-
lications were also assessed by a second assessor (SJ).
To get insight into the clinical use and clinical validation of
these screening tools, we contacted the authors of the publi-
cations. For those screening tools, we were unable to contact
the author we made an additional search from the Medline
database to find the publications that cited the original screen-
ing tool. From these sources, we were able to find publications
describing clinical use or validation in patient surroundings.
Data extraction and analysis
Country of origin, criteria contents, setting in which the tool is
meant to be used, development methods, and the evidence
used to determine the criteria, nature of the criteria (explicit/
implicit), the primary user of the tool, and information on the
primary validity or reliability of the tool were analyzed. Also
information on clinical use and validation was extracted.
Results
This systematic review identified 15 publications describing
11 DRP risk assessment tools, 10 of which were specially
designed for older adults aged 60 years and above (Fig. 1,
Tables 2 and 3 and Online Resource 1). The general tool,
Table 1 Inclusion and exclusion
criteria used in the literature
search
Inclusion criteria Exclusion criteria
Patients ≥ 60 years old (evidence-based medicine,
Scopus, Web Of Science, Medline). Patients
≥ 65 years old (CINAHL)
Patients < 60 years old. (CINAHL <65 years old)
English Language other than English
Describes a general drug-related problem risk
assessment tool
Describes a disease, therapy, and drug-specific tool or
a tool focusing solely on inappropriate prescribing
or adherence
Describes the end user of the tool and in what setting it
is meant to be used
Does not describe by whom and in what setting the
tool is meant to be used
Published between January 1, 1985–April 7, 2016
(CINAHL January 1, 1985–October 29, 2013)
Published before January 1,1985, or after April 7, 2016
The tool focuses on older population in general The tool focuses on other than older population or only
on a certain part of the older population, e.g., having
the same disease or drug therapy
Published in a peer-reviewed journal Published in other than peer-reviewed journal
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without age specifications, was the earliest tool, published in
1989 [9] and used as a foundation for four other tools devel-
oped later [15, 27, 35, 38].
Seven of the tools (64%) were intended to be used in pri-
mary care, mostly in home care or community nursing (n = 4)
[20, 33, 34, 38] (Table 2). Three of the tools targeted ambula-
tory care [9, 14, 15], one focused on intermediate care [27],
and one targeted computer screening of risks for DRPs [34].
Nearly all (n = 10/11) of the tools were developed to be used
explicitly [9, 15, 17, 20, 27, 30, 33–35, 38]. Two of the tools
had an established scoring systemmaking the interpretation of
the results explicit [14, 17]. Four of the tools were designed to
be completed by the patient [15, 27, 30, 35]. Four tools were
designed to be used by pharmacists [9, 14, 17, 34] or nurses
[17, 20, 33, 38], while two of the tools had several possible
end users [17, 38].
Contents of the tools
The risk assessment tools encompassed 4–71 criteria, seven of
the tools containing less than 20 criteria (Tables 3 and Online
Resource 1). These criteria were divided into three main risk
ca t ego r i e s : p a t i e n t o r c a r eg ive r - r e l a t ed r i sk s ,
pharmacotherapy-related risks, and medication use process-
related risks (Online Resource 1). The patient or caregiver-
related risks included older age, multiple comorbidities, and
Potentially relevant publications (n=4279) 
(Evidence Based Medicine (EBM), n=81; Medline, n=519; Web of Science (WOS), n=191; Scopus, n=727; Cinahl, 
n=2761)
Assessment of titles
Excluded according to the titles (n=4083) 
(EBM, n=69; Medline, n=439; WOS, n=145; Scopus, n=677; Cinahl, n=2753) 
Potentially relevant publications according to the titles (n=196) 
(EBM, n=12; Medline, n=80; WOS, n=46; Scopus, n=50; Cinahl, n=8) 
Assessment of abstracts 
Excluded according to the abstracts (n=108) 
(EBM, n=2; Medline, n=55; WOS, n=24; Scopus, n=25; Cinahl, n=2) 
Potentially relevant publications according to the abstract (n=88) 
EBM, n=10; Medline, n=25; WOS, n=22; Scopus, n=25; Cinahl, n=6)
Potentially relevant publications, whole text retrieved (n=54) 
Excluded publications: duplications (n=34) 
Excluded publications (n=44) 
(1) Interventions to optimize prescribing for older patients (n=3); (2) Tool not specified for older 
adults (n=14); (3) The publication did not contain a tool for assessing risk for drug-related problems 
(n=16); (4) Screening for high hospital use or readmission (n=5); (5) Use of a pre-existing tool with 
no additional information provided (n=4); (6) Published in a non-peer-reviewed journal (n=1); (7) 
Language other than English (n=1) 
Publications meeting the inclusion criteria (n=10) 
Publications meeting inclusion criteria found from the references or additional publications provided 
by the authors of the included studies (n=5)  
Publications meeting the inclusion criteria (n=15) describing altogether 11 screening tools 
Fig. 1 Flowchart of the study
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medication adherence or self-management problems as risk
factors for clinically significant DRPs. The items concerning
medication adherence and self-management demonstrated
more variety between the tools compared to any other risk
categories. Pharmacotherapy-related risks most commonly in-
dicated risks caused by polypharmacy, potentially inappropri-
ate medications for older adults (PIMs), potential ADRs, and
recent changes in medication regimen. Most common PIMs
listed in the tools included carbamazepine (n = 3) [15, 27, 38],
digoxin (n = 3) [15, 27, 38], lithium (n = 3) [15, 27, 38], the-
ophylline (n = 3) [15, 27, 38], and warfarin (n = 3) [15, 27,
38]warfarin (n = 3) (ref). The most common potential ADRs
were classified as drowsiness (n = 2) [30, 38], visual problems
(n = 2) [14, 38], nausea (n = 2) [30, 38], constipation (n = 2)
[30, 38], skin rash (n = 2) [30, 38], and dizziness (n = 2) [30,
38]. The tools included a few risks related to the medication
use process such as health service visits, number of physicians
involved in patient’s care, and living arrangements.
The most common risks that appeared in at least four of the
tools were established (Tables 3 and Online Resource 1).
“Problems remembering to take the medication”was the most
frequent item and was included in seven of the tools [14, 20,
27, 30, 33, 35, 38]. Only one of the tools gave options for
resolving the risks identified [38].
Validity and reliability
The primary validity of the tool was assessed more com-
monly (n = 9) than reliability (n = 6) (Tables 2 and 3). For
one of the tools, validation was not reported [14], and
reliability was not assessed for five of the tools [9, 14,
20, 34, 35]. There seemed to be no consistent type of
validity or reliability assessment. Content validation (n =
9) [9, 15, 17, 27, 30, 34, 35, 38] and assessing the appli-
cability of the tool (n = 3) [30, 33, 38] were the most
common types of validation. Internal consistency (n = 3)
[15, 17, 27] and inter-rater reliability (n = 2) [15, 17] were
the most common types of reliability assessment.
The outcome variables used for primary validation varied
from study to study. For example, number of recognized risk
factors (intervention group vs. control group) and measures
used to assess adherence and medication regimen complexity
were used as outcomes in different studies. Also it is worth
noting that validation of the scoring was not reported for both
tools that had a scoring system [14, 17]. The most compre-
hensive evaluation of primary validity and reliability were
done in Barenholz-Levy’s, Fuller and Watson’s, Gusdal’s,
and Dimitrow’s research [15, 17, 33, 38].
Additional clinical validation [10, 41] was done only for
two of the screening tools (Table 4) [15, 38]. Three of the tools
[9, 15, 38] were reported in clinical use in scientific publica-
tions [42–50].
Discussion
This is the first systematic review evaluating and comparing
the content and development processes of published criteria
for DRP risk assessment for older adults. It provides insights
into the evidence and content of DRP risk assessment tools.
This information is important because these tools maybe used
for clinical decision making, by screening older adults at risk
for DRPs.
Our systematic review found considerable variety in the
number and contents of the criteria included in the risk assess-
ment tools; only eight of the risks were similar between the
tools (Problemswith remembering to take the medication (n =
7) [14, 20, 27, 30, 33, 35, 38], Not knowing indications for the
medicines (n = 5) [15, 27, 30, 33, 38], More than one physi-
cian involved in patient's care (n = 5) [15, 20, 27, 30, 38], ≥ 12
doses per day (n = 5) [9, 15, 20, 27, 38], ≥ 5 medicines in use
(n = 4) [9, 15, 27, 30], ≥ 3 illnesses (n = 4) [15, 27, 30, 38], ≥ 4
changes in the medication regimen within the last year (n = 4)
[9, 15, 27, 30], and Problems taking medicine out of the bottle
or using a dose dispenser or therapeutic devises (n = 4) [14,
30, 33, 38]). The different settings and end users they were
designed for may partly explain the variety in the content of
the tools. Four of the tools were designed for patients [15, 27,
30, 35], and the rest for healthcare professionals [17, 20, 33,
38]. The earliest tool was published two decades ago [9], and
the most recent was published in 2014 [38]. This time period
corresponds to the publication of criteria used in the assess-
ments of PIMs, which may partially explain the different con-
tent of the tools. Five of the tools used previously published
tools as a basis for the development [15, 20, 27, 35, 38]. This
may be considered a strength if the tool used as a foundation
was developed through a rigorous method and is well validat-
ed. The data that is used should not be outdated but represent
the knowledge of risks for DRPs in the elderly population at
the time of publication. The critical evaluation of the previous
criteria is needed if the specific criteria are to be used as a
foundation for a new risk assessment tool. The use of previous
tools might bring more evidence and validity for the new tool
but might also limit the ingenuity and timeliness of the con-
tents of the new tools.
The primary validity and reliability assessments of the tools
varied substantially. Content validation was done for most of
the tools (n = 9/11) [9, 15, 17, 20, 27, 30, 34, 35, 38], while
two of the tools [14, 33] were not assessed for content validity
which is a significant limitation [51]. Five of the tools [9, 30,
33, 35, 38] used expert opinion in their development process,
but only one of them was further validated using the Delphi
method [38]. Two other tools used expert opinion consensus
to rank the items that would be included in the final tool in one
or more rounds [9, 33]. A recent review on methodology to
assess content validity highlights the importance of determin-
ing content validity for new instruments [51]. The
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Table 3 Summary of the characteristics of the drug-related problem risk assessment tools (n = 11)
Country of origin USA (n = 5) [9, 14, 15, 34, 35]
UK (n = 2) [17, 27]
Australia (n = 2) [20, 30]
Sweden (n = 1) [33]
Finland (n = 1) [38]
Setting Primary care Homecare or community nursing (n = 4) [20, 33, 34, 38]
General practitioner’s surgery (n = 1) [30]
Medicare beneficiaries (n = 1) [35]
Primary care and social care (n = 1) [17]
Ambulatory care (n = 3) [9, 14, 15]
Intermediate care/sheltered housing (n = 1) [27]
Use of the tool implicit / explicit Explicit (n = 10) [9, 15, 17, 20, 27, 30, 33–35, 38]
Implicit (n = 1) [14]
Number of criteria 1–4 criteria (n = 1) [20]
5–9 criteria (n = 3) [9, 17, 35]
10–14 criteria (n = 1) [15]
15–19 criteria (n = 2) [27, 33]
20–29 criteria (n = 1) [38]
30–34 criteria (n = 1) [30]
≥ 35 criteria (n = 1) [14]
Unknown (n = 1) [34]
The most common risks that
appeared in at least four
of the tools
Problems with remembering to take the medication (n = 7) [14, 20, 27, 30, 33, 35, 38]
Not knowing indications for the medication (n = 5) [15, 27, 30, 33, 38]
More than one physician involved in patient's care (n = 5) [15, 20, 27, 30, 38]
≥ 12 doses per day (n = 5) [9, 15, 20, 27, 38]
≥ 5 medicines in use (n = 4) [9, 15, 27, 30]
≥ 3 illnesses (n = 4) [15, 27, 30, 38]
≥ 4 changes in the medication regimen within the last year (n = 4) [9, 15, 27, 30]
Problems taking medicine out of the bottle or using a dose dispenser or therapeutic
devises (n = 4) [14, 30, 33, 38]
End user of the tool* Patient (n = 4) [15, 27, 30, 35]
Pharmacist (n = 4) [9, 14, 17, 34]
Nurse (n = 4) [17, 20, 33, 38]
Practical nurse (n = 1) [38]
Physician (n = 1) [17]
Social service carer (n = 1) [17]
Community therapist (n = 1) [17]
Validity assessment** Content validation (n = 9) [9, 15, 17, 20, 27, 30, 34, 35, 38]
Applicability of the tool (n = 3) [30, 33, 38]
No reported validity assessment (n = 1) [14]
Reliability assessment** Internal consistency (n = 3) [15, 17, 27]
Inter-rater reliability (n = 2) [15, 17]
Intra-rater reliability (n = 1) [17]
Test-retest reliability (n = 1) [15]
Inter-item correlation (n = 1) [33]
Other assessments (n = 2) [30, 38]
No reported reliability assessment (n = 5) [9, 14, 20, 34, 35]
*Results do not add up to 11 since there could have been several possible end users
**Results do not add up to 11 since several assessments of validity and reliability could have been undertaken
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recommendation of the authors was that content validity pro-
cesses and indices are critical factors in the instrument devel-
opment process and should be treated and reported as other
types of construct validation. It is also important to keep in
mind that every technique used in developing a risk assess-
ment tool has its own limitations [52]. For example, the
criteria developed through literature review may not evaluate
the quality of evidence. Furthermore, consensus panels, such
as Delphi method, only provide knowledge on the opinion of
those experts included in the process at that moment in time.
These aspects of instrument validation should be considered
when deciding which tools will be used in clinical practice.
Very few tools were additionally validated or used in clinical
settings (Table 4). This presents a further limitation for the
evidence-based use of these risk assessment tools.
Most tools (n = 7/11) [17, 20, 30, 33–35, 38] were designed
to be used in different primary care settings (homecare or
community nursing (n = 4) [20, 33, 34, 38], general practi-
tioner’s surgery (n = 1) [30], Medicare beneficiaries (n = 1)
[35], and primary care and social care (n = 1) [17]) which
may partly explain the variety in the risks for DRPs found in
the tools. This is in line with findings from Devik et al. [53]
fromNorway and Leikola et al. from Finland [54]. Both found
that DRPs identified in older adults varied in number and in
nature depending on whether the patients resided at home or
nursing home. These findings demonstrate that the transfer of
a tool to a new setting must be accompanied by a new valida-
tion of the applicability [51]. That is why tools validated in
different settings and for different end users need to be avail-
able, which was demonstrated in our systematic review. Also
the content and feasibility of the risk assessment tools require
regular updating with new research data, pharmacotherapies,
and current care guidelines.
No consensus existed in potential ADRs and potentially
harmful medication categories listed in the tools. No single
risk medication appeared in more than three of the tools, and
no single ADR appeared in more than two tools (Online
Resource 1). The most common risks for DRPs in the tools
were focused on the number of regularly used medicines (n =
4) [9, 15, 27, 30], number of doses (n = 5) [9, 15, 20, 27, 38],
Table 4 Clinical validation and use of the DRP risk assessment tools
Author of the tool Information source:
author or Medline
Clinical validation Clinical use
Koecheler et al. 1989 [9] Medline (30 search results) None Malone et al. [42] IMPROVE
study of which there is
considerable amount published [43–47]
Sidel et al. 1990 [14] Medline (13 search results) None None
Barenholz Levy 2003 [15] Author Barenholz Levy and Steffen: significant
correlation with perceived medication
management hassles and reports
of care recipients’ falls, injuries,
emergency department visits, unplanned
healthcare visits, CDC Healthy Days,
and amount of unused medications that
interfere with current medication
management. [41]
Moore et al. [48]. Tan et al. [49]
Fuller and Watson 2005 [17] Author None None
Johnson et al. 2005 [20] Medline (10 search results) None None
George et al. 2006 [27] Medline (6 search results) None None
Pit et al. 2007 [30] Medline (5 search results) None None
Gusdal et al. 2011 [33] Medline (5 results) None None
Lukazewski et al. 2012 [34] Author None None
Doucette et al. 2013 [35] Author None None
Dimitrow et. al. 2014 [38] Author Dimitrow et al.: additional content
validation by geriatrician’s appraisal
of relevance of the questions. Feasibility
according to a geriatrician’s assessment
of the clinically important information
the tool presented. Validity in patient
surroundings and comparison to a
geriatricians risk appraisal with or
without the DRP-RAT. [10]
Toivo et al. [50]
Eur J Clin Pharmacol (2020) 76:337–348 345
and problems remembering to take the medicines (n = 7) [14,
20, 27, 30, 33, 35, 38]. However, the number of medicines a
patient is taking has a limited ability to represent the risk for
DRPs [55]. When the patient’s medication regimen is planned
appropriately, polypharmacy should not be harmful. On the
other hand, if the criterion for the risk for DRPs is set, e.g., to
10 medicines, it will exclude many patients at potential risk
who have fewer medicines [10]. Two recently established sets
of core outcomes measures for trials aimed at improving the
appropriateness of polypharmacy in older adults [56] could be
useful in guiding further criteria development and standardi-
zation of criteria.
Strengths and limitations
The thorough pilot testing of the search terms, systematic data
abstraction, and analysis according to PRISMAGuidelines [7,
8] resulted in a robust search strategy and systematic review
process. Notwithstanding this, a variety of terms used to de-
scribe DRPs or different kinds of risk assessments for DRPs
[5] means that some publications may not have been identi-
fied. However, to improve the coverage, we also searched the
references of the included articles and contacted the authors in
unclear situations. The language was restricted to English, so
possible studies published in other languages were excluded.
Because of the lack of potentially relevant publications in the
CINAHL database in the first phase of the literature search in
2013, it was excluded from the newer search covering the
years 2013–2016. The publications were assessed for inclu-
sion by two authors (EP and SJ) by using predetermined in-
clusion and exclusion criteria. However, data were extracted
from the included publications and analyzed by only one of
the authors (EP). This might have created bias in this study.
Future studies
Establishment of new criteria should be continued since only
11 risk assessment tools were located, of which seven tools
were developed over 10 years ago and two over 5 years ago.
There was considerable variety in essential factors that could
cause risk for DRPs. This systematic review provides a good
foundation on which to create a better consensus. Current
research and recommendations concerning PIM criteria and
DRP classifications needs to be taken into account in future
research projects.
Conclusions
The considerable variety between the content of the assess-
ment tools indicates that there was no consensus on the risk
factors for DRPs that should be screened in older adults.
Further research is needed to improve the appropriateness
and timeliness of the DRP risk assessment tools.
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